Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2008

Merck Partners with Nuevolution for Access to Chemetics Platform

  • Merck inked a drug discovery collaboration with Nuevolution to gain access to its  Chemetics® drug discovery technology. The firms will collaborate to identify small molecule leads against several drug targets of interest to Merck. Chemetics uses DNA labeling to allow fragment-based drug screening.

    Nuevolution will screen multiple multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis, and screening of target-focused Chemetics follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

    Merck will fund the research with an upfront payment to Nuevolution and will make milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. Additionally, Nuevolution is eligible to receive royalties on the commercial sales of approved products.

    Related Links:

    Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals

    Fragment-Based Approach Increases Leads



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »